Aynehchi BB, Cerrati EW, Rosenberg DB. The efficacy of oral celecoxib for acute postoperative pain in face-lift surgery.
JAMA FACIAL PLAST SU 2015;
16:306-9. [PMID:
25010711 DOI:
10.1001/jamafacial.2014.351]
[Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE
Exploring methods of potentially improving patient comfort and pain control in cosmetic facial surgery.
OBJECTIVE
To examine the effects of celecoxib in reducing pain and possible opioid consumption following face-lift surgery.
DESIGN, SETTING, AND PARTICIPANTS
We reviewed the medical records of 100 patients: 50 consecutive patients who underwent a face-lift without receiving perioperative celecoxib and 50 patients who underwent face-lift and received immediate preoperative and standing postoperative celecoxib.
MAIN OUTCOMES AND MEASURES
In addition to demographic information, the following outcome measures were recorded for each group: visual analog scale patient-reported pain, acetaminophen and/or opioid consumption rates, and related analgesic adverse effects.
RESULTS
The participants in the noncelecoxib vs celecoxib groups had similar demographic characteristics: mean age, 59.6 vs 57.9 years; mean BMI, 23.3 vs 22.3; history of chronic pain or opioid use, 7 (14%) vs 6 (12%); and 94% of both groups were women. Postoperative pain scores were higher in the noncelecoxib vs celecoxib groups; mean (SD) overall pain score was 3.88 (2.20) vs 2.31 (2.36) (P < .001). The noncelecoxib group had a higher number of postoperative opioid doses than did the celecoxib group: 9.40 (4.30) vs 5.18 (4.58) (P < .05). The noncelecoxib group had a higher incidence of postoperative nausea and vomiting: 12 (24%) vs 0 in the celecoxib group.
CONCLUSIONS AND RELEVANCE
Preemptive treatment with oral celecoxib appears to be effective in decreasing acute postoperative pain and opioid consumption in patients undergoing face-lift. Given the well-documented adverse effects of opioids, celecoxib is a desirable alternative.
LEVEL OF EVIDENCE
3.
Collapse